In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
Opinion|Videos|February 21, 2025 (Updated: January 31, 2025)
Real World Experience of CAR-T in MM Patients
This segment examines Dr. Mikhael's approach to comparing ide-cel and cilta-cel for patient selection, emphasizing how patient traits, efficacy, and safety profiles influence treatment decisions across different groups.
Advertisement
Video content above is prompted by the following:
- How would you assess ide-cel versus cilta-cel when it comes to selecting patients?
- Are there any patient traits that might steer you toward one CAR-T product over the other?
- In what ways do the efficacy and safety profiles of these treatments impact your choices for different patient groups?
Advertisement
Related to this article
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Advertisement
Advertisement
Trending on CancerNetwork
1
Building Systems to Catch Liver and Other Cancers in Patients With MASLD
2
Closing the HCC Surveillance Gap in MASLD Without Cirrhosis
3
Rethinking Surveillance and Multidisciplinary Care in MASLD-Related HCC
4
Weighing HCC Surveillance for Patients With MASLD and F3 Fibrosis
5